Compare WKEY & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | VANI |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Switzerland | United States |
| Employees | 202 | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 100.0M |
| IPO Year | N/A | 2014 |
| Metric | WKEY | VANI |
|---|---|---|
| Price | $9.87 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.50 | $3.50 |
| AVG Volume (30 Days) | 147.4K | ★ 185.3K |
| Earning Date | 01-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.75 | $0.92 |
| 52 Week High | $19.80 | $1.92 |
| Indicator | WKEY | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 54.76 |
| Support Level | $6.84 | $1.20 |
| Resistance Level | $10.11 | $1.55 |
| Average True Range (ATR) | 0.75 | 0.06 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 68.94 | 79.28 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.